Trial: A Study to Evaluate Sacituzumab Tirumot…

Trial Details

Sponsor: Merck Sharp & Dohme LLC (industry)

Phase: 3

Start date: May 3, 2024

Planned enrollment: 450

Trial ID: NCT06356311

More trial details at ClinicalTrials.gov

Show Summary from Sponsor

Investigational Drug AI Analysis

Show for: Sacituzumab tirumotecan (SKB264, MK-2870, sac-TMT)

Overview

Sacituzumab tirumotecan (sac-TMT; SKB264; MK-2870) is a TROP2-directed antibody–drug conjugate (ADC) that couples the same anti‑TROP2 monoclonal antibody used in sacituzumab govitecan to a belotecan‑derived topoisomerase I inhibitor payload (KL610023) via a sulfonyl‑pyrimidine–CL2A–carbonate linker; the average drug‑to‑antibody ratio (DAR) is ~7.4. Early- and late‑phase studies report antitumor activity across multiple solid tumors, most notably triple‑negative breast cancer (TNBC), hormone‑receptor–positive/HER2‑negative (HR+/HER2–) breast cancer, non–small cell lung cancer (NSCLC), and urothelial carcinoma. (jhoonline.biomedcentral.com)

Regulatory note: Sacituzumab tirumotecan received approval in China (November 2024) for pretreated advanced TNBC; it remains investigational in the United States with multiple ongoing phase 3 trials. (onclive.com)

Mechanism of action

Target: TROP2, broadly expressed in epithelial cancers. (jhoonline.biomedcentral.com)
Payload/linker: Belotecan‑derived topoisomerase I inhibitor (KL610023) linked via an irreversible methylsulfonyl‑pyrimidine chemistry designed to enhance conjugate stability and enable membrane‑permeable payload release (bystander effect). DAR ~7.4. (pmc.ncbi.nlm.nih.gov)

Efficacy

Breast cancer
- Phase 1/2 (first‑in‑human, MK‑2870‑001; data cutoff June 29, 2023):
- TNBC expansion: ORR 34.8% at 4 mg/kg (n=23) and 38.9% at 5 mg/kg (n=36). (jhoonline.biomedcentral.com)
- HR+/HER2– expansion: ORR 31.7% (n=41); median DOR 9.5 months; median PFS 8.0 months; median OS 13.9 months. (jhoonline.biomedcentral.com) - Phase 3 (OptiTROP‑Breast01; randomized vs physician’s‑choice chemotherapy; TNBC):
- PFS (BICR): 5.7 vs 2.3 months; HR 0.31 (95% CI 0.22–0.45).
- ORR: 43.8% vs 12.8%.
- Interim OS: HR 0.53 (95% CI 0.36–0.78). (ascopubs.org)

Lung cancer
- Phase 1b/2 (ASCO 2024; treatment‑naive metastatic NSCLC) sac‑TMT + KL‑A167 (anti‑PD‑1):
- Cohort 1A and 1B showed ORR 48.6% and 77.6%, respectively; 6‑month PFS rates 69.2% and 84.6%. A phase 3 study of sac‑TMT + pembrolizumab in first‑line PD‑L1 TPS ≥50% NSCLC is ongoing (NCT06170788). (ovid.com)
- Nature Medicine publications (April 2025) reported results in previously treated metastatic TNBC (phase 3) and advanced NSCLC (phase 1/2 and phase 2); DOIs: 10.1038/s41591‑025‑03630‑w (TNBC) and 10.1038/s41591‑025‑03638‑2 (NSCLC). (nature.com)

Urothelial carcinoma
- ASCO GU 2025 (MK‑2870‑001 cohort): sac‑TMT 5 mg/kg Q2W in previously treated unresectable/metastatic UC:
- Second‑line (n=11): ORR 45.5% (1 CR, 4 PR).
- Third‑line or later (n=38): ORR 26.3%.
- Median PFS ~5.0–5.8 months; median OS 11.5 months (3L+). (ascopubs.org)

Safety

Across studies, the most common treatment‑related grade ≥3 adverse events include myelosuppression (neutrophil count decreased, white blood cell count decreased) and anemia; dermatologic events and stomatitis occurred in early dose‑finding.

Phase 1/2 (MK‑2870‑001): grade 3/4 TRAEs in 52% (4 mg/kg) and 67% (5 mg/kg) in TNBC expansion; no grade 5 TRAEs. HR+/HER2– cohort: grade 3/4 TRAEs in 54%; no grade 5 TRAEs. Reported DLTs included grade 3 stomatitis and rash; MTD 5.5 mg/kg; recommended expansion doses 4 and 5 mg/kg. (jhoonline.biomedcentral.com)
Phase 3 TNBC (OptiTROP‑Breast01): common grade ≥3 TRAEs with sac‑TMT were neutrophil count decreased (32.3%), anemia (27.7%), and white blood cell count decreased (25.4%); rates were comparable or lower than chemotherapy for hematologic events; no new safety signals reported. (ascopubs.org)
Urothelial carcinoma (ASCO GU 2025): treatment‑related grade ≥3 AEs in 59.2%; most common were anemia (38.8%) and decreased neutrophil count (28.6%); no treatment‑related deaths reported at cutoff. (ascopubs.org)

HealthScout AI Analysis

Goal: Evaluate whether sacituzumab tirumotecan (MK-2870), a TROP2-directed antibody-drug conjugate, improves overall survival versus treatment of physician’s choice in patients with previously treated advanced/metastatic gastroesophageal adenocarcinoma (3rd line or later).

Patients: Adults with histologically or cytologically confirmed advanced, unresectable, or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma; measurable disease by RECIST 1.1; progression after at least two prior systemic regimens (chemotherapy and/or immunotherapy). HER2-positive patients must have received trastuzumab where appropriate. ECOG 0–1 and adequate organ function required. Key exclusions include significant ocular surface disease impairing corneal healing, grade ≥2 neuropathy, active IBD, uncontrolled cardiovascular/cerebrovascular disease, symptomatic effusions requiring recent drainage, prior TROP2-directed ADC or topoisomerase I inhibitor-based ADC/chemotherapy, active CNS metastases, active infections, recent major surgery, severe hypersensitivity to study drugs, and history or current steroid-requiring pneumonitis/ILD.

Design: Multicenter, open-label, randomized Phase 3 study with allocation to sacituzumab tirumotecan versus treatment of physician’s choice. Stratification includes centrally assessed TROP2 status. Planned enrollment approximately 450 participants.

Treatments: Experimental: Sacituzumab tirumotecan 4 mg/kg IV on days 1, 15, and 29 of each 42-day cycle, with supportive care and rescue medications as needed. Sacituzumab tirumotecan is a TROP2-targeted antibody-drug conjugate linking an anti-TROP2 antibody to a belotecan-derivative topoisomerase I inhibitor via a cleavable linker (average drug-to-antibody ratio ~7.4). The linker allows extracellular pH-sensitive and intracellular enzymatic release of a membrane-permeable payload, enabling bystander killing. In Phase 3 TNBC, sacituzumab tirumotecan improved PFS and OS versus chemotherapy, with common grade ≥3 AEs including neutropenia, anemia, and leukopenia; early-phase lung and breast cancer studies have also shown high response rates, supporting further evaluation in gastrointestinal cancers. Control: Treatment of physician’s choice with one of trifluridine–tipiracil, irinotecan, paclitaxel, or docetaxel given at standard dosing schedules.

Outcomes: Primary: Overall survival. Key secondary: PFS by BICR per RECIST 1.1, objective response rate by BICR, duration of response by BICR, incidence of adverse events, and treatment discontinuations due to AEs. Follow-up for efficacy up to approximately 25–31 months, and safety up to approximately 48 months.

Burden on patient: Moderate. Participants will undergo standard-of-care intensity imaging for RECIST assessments and routine labs; a pretreatment tumor tissue sample for centralized TROP2 testing is required, which may necessitate obtaining archival tissue or a new biopsy. The experimental arm involves IV infusions on days 1, 15, and 29 of 42-day cycles, resulting in roughly three clinic visits every six weeks; control regimens vary from oral trifluridine–tipiracil with clinic monitoring to weekly or biweekly IV chemotherapy, which also entails frequent visits. No intensive pharmacokinetic sampling is described, but safety monitoring is expected given ADC-associated myelosuppression and potential ocular and pulmonary risks, leading to periodic ophthalmic assessments and frequent blood counts. Overall visit frequency and testing are comparable to later-line standard oncology care, with added logistic burden from centralized biomarker submission and the triweekly infusion cadence in the experimental arm.

Last updated: Oct 2025

Eligibility

Show Criteria

Inclusion Criteria:

* Has a histologically-or cytologically-confirmed diagnosis of advanced, unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma

* Has measurable disease per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by the local site investigator/radiology. Lesions situated in a previously-irradiated area are considered measurable if progression has been shown in such lesions.

* Has received, and progressed on, at least 2 prior chemotherapy and/or immunotherapy regimens for advanced, unresectable or metastatic gastroesophageal adenocarcinoma.

* Participants are eligible regardless of human epidermal growth factor receptor-2 (HER2) status. Participants who are HER2+ must have previously received trastuzumab where available/appropriate

* Has adequate organ function

* Has provided tumor tissue sample for determination of trophoblast cell-surface antigen 2 (TROP2) status by the central laboratory before randomization for stratification

* Participants who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or baseline (except for alopecia and vitiligo). Participants with endocrine related AEs who are adequately treated with hormone replacement therapy are eligible

* Has measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by the local site investigator/radiology

* Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 3 days before randomization

* Has ability to swallow oral medication for those who may receive trifluridine-tipiracil

* Human immunodeficiency virus (HIV) infected participants must have well-controlled HIV on antiretroviral therapy (ART)

* Hepatitis B surface antigen (HBsAg) positive participants are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load

* Participants with a history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable

Exclusion Criteria:

* Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing

* Has Grade ≥2 peripheral neuropathy

* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea)

* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of corrected QT interval (QTcF) to \>480 ms, and/or other serious cardiovascular and cerebrovascular diseases within 6 months before the first dose of study intervention

* Has accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks before the first dose of study intervention

* Has received prior treatment with a trophoblast antigen 2(TROP2) targeted antibody-drug conjugate (ADC), a topoisomerase 1 inhibitor based, and/or a topoisomerase 1 inhibitor-based chemotherapy.

* Has received prior systemic anticancer therapy within 2 weeks before the first dose of study intervention

* Has received prior radiotherapy within 2 weeks before the first dose of study intervention, has radiation-related toxicities, requiring corticosteroids, and/or has had radiation pneumonitis

* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention

* Is currently receiving a strong and/or moderate inducer/inhibitor of cytochrome P450 3A4 (CYP3A4) that cannot be discontinued for the duration of treatment with study intervention. The required washout period before starting study intervention is 2 weeks

* Has received an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention

* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years

* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis

* Has an active infection requiring systemic therapy

* HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castlemans's Disease

* Has concurrent active hepatitis B (defined as hepatitis B surface antigen (HBsAg) positive and/or detectable HBV deoxyribonucleic acid (DNA)) and Hepatitis C virus (HCV) defined as anti-HCV antibody (Ab) positive and detectable HCV ribonucleic acid (RNA)) infection

* Has had major surgery or significant traumatic injury within 4 weeks before the first dose of study intervention. Anticipation of the need for major surgery during the course of treatment with study intervention is also exclusionary

* Has severe hypersensitivity (Grades \>=3) to the study interventions, any of their excipients, and/or to another biologic therapy

* Has a history of (noninfectious) pneumonitis/ interstitial lung disease (ILD) that required steroids or has current pneumonitis/ILD

Sites (166)

Sort by distance to:

Cliniques universitaires Saint-Luc-Medical Oncology ( Site 1001)

Brussels, Bruxelles-Capitale, Region de, 1200, Belgium

No email / 1-888-577-8839

Status: Recruiting

Institut Jules Bordet-GastroIntestinal Medical Oncology ( Site 1003)

Anderlecht, Bruxelles-Capitale, Region de, 1070, Belgium

No email / 1-888-577-8839

Status: Recruiting

UZ Leuven-Digestive Oncology ( Site 1000)

Leuven, Vlaams-Brabant, 3000, Belgium

No email / 1-888-577-8839

Status: Recruiting

AZ Delta vzw ( Site 1002)

Roeselare, West-Vlaanderen, 8800, Belgium

No email / 1-888-577-8839

Status: Recruiting

A. C. Camargo Cancer Center ( Site 0409)

São Paulo, 01509-010, Brazil

No email / +551121895000

Status: Recruiting

IBCC - Núcleo de Pesquisa e Ensino ( Site 0402)

São Paulo, 04014-012, Brazil

No email / +551144500360

Status: Recruiting

Centro de Pesquisa Clínica do Instituto do Câncer do Ceará ( Site 0405)

Fortaleza, Ceará, 60430235, Brazil

No email / 558532884576

Status: Recruiting

Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0406)

Natal, Rio Grande do Norte, 59075-740, Brazil

No email / +55 84 99119-1032

Status: Recruiting

Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0400)

Porto Alegre, Rio Grande do Sul, 91350-200, Brazil

No email / 555133572092

Status: Recruiting

Hospital de Caridade de Ijuí ( Site 0412)

Ijuí, Rio Grande do Sul, 98700 000, Brazil

No email / +5555981580022

Status: Recruiting

Centro de Hematologia e Oncologia ( Site 0404)

Joinville, Santa Catarina, 89202-050, Brazil

No email / +554734331849

Status: Recruiting

Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0411)

São José do Rio Preto, São Paulo, 15090000, Brazil

No email / +55 11 99772-2237

Status: Recruiting

McGill University Health Centre ( Site 0201)

Montreal, Quebec, H4A 3J1, Canada

No email / 514-934-1934 x45721

Status: Recruiting

Bradfordhill-Clinical Area ( Site 0501)

Santiago, Region M. de Santiago, 8420383, Chile

No email / 1-888-577-8839

Status: Recruiting

Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0503)

Santiago, Region M. de Santiago, 7500653, Chile

No email / +56991612199

Status: Recruiting

Clínica UC San Carlos de Apoquindo-Hemato-Oncology ( Site 0502)

Santiago, Region M. de Santiago, 7620002, Chile

No email / 1-888-577-8839

Status: Recruiting

FALP-UIDO ( Site 0500)

Santiago, Region M. de Santiago, 7500921, Chile

No email / 1-888-577-8839

Status: Recruiting

James Lind Centro de Investigacion del Cancer ( Site 0506)

Temuco, Región de la Araucanía, 4800827, Chile

No email / 1-888-577-8839

Status: Recruiting

Anhui Provincial Cancer Hospital-medical oncology ( Site 3016)

Hefei, Anhui, 230000, China

No email / +8618110410760

Status: Recruiting

Second Affiliated hospital of Anhui Medical University-Oncology ( Site 3038)

Hefei, Anhui, 230000, China

No email / 0551-63839536

Status: Recruiting

Chongqing University Three Gorges Hospital ( Site 3036)

Chongqing, Chongqing Municipality, 404000, China

No email / 023-58103019

Status: Recruiting

Fujian Cancer Hospital ( Site 3007)

Fuzhou, Fujian, 350014, China

No email / +86059183660063

Status: Recruiting

The 900th Hospital of the Joint Logistics Support Force of PLA ( Site 3008)

Fuzhou, Fujian, 350025, China

No email / +86 0591-22859606

Status: Recruiting

The First Affiliated hospital of Xiamen University-oncology ( Site 3011)

Xiamen, Fujian, 361003, China

No email / +860592213727

Status: Recruiting

Zhongshan Hospital Affiliated to Xiamen University ( Site 3013)

Xiamen, Fujian, 361004, China

No email / +86 0592-2211200

Status: Recruiting

Cancer Hospital of Shantou University Medical College ( Site 3034)

Shantou, Guangdong, 515041, China

No email / +86 0754-88573563

Status: Recruiting

Southern Medical University Nanfang Hospital-Department of Oncology ( Site 3019)

Guangzhou, Guangdong, 510515, China

No email / +862061641888

Status: Recruiting

Sun Yatsen University Cancer Center ( Site 3001)

Guangzhou, Guangdong, 510555, China

No email / 02087342479

Status: Recruiting

Affiliated Cancer Hospital of Guangxi Medical University ( Site 3047)

Nanning, Guangxi, 530201, China

No email / +86 0771-5331955

Status: Recruiting

Fourth Hospital of Hebei Medical University ( Site 3015)

Shijiazhuang, Hebei, 050035, China

No email / +8613831120299

Status: Recruiting

Harbin Medical University Cancer Hospital-Harbin Medical University Cancer Hospital ( Site 3005)

Harbin, Heilongjiang, 150081, China

No email / 0451 86298278

Status: Recruiting

Henan Cancer Hospital-henan cancer hospital ( Site 3002)

Zhengzhou, Henan, 450000, China

No email / +864000371818

Status: Recruiting

Hubei Cancer Hospital ( Site 3012)

Wuhan, Hubei, 430079, China

No email / +8613995607152

Status: Recruiting

Xiangyang Central Hospital ( Site 3045)

Xiangyang, Hubei, 441106, China

No email / 0710-2815626

Status: Recruiting

Hunan Cancer Hospital ( Site 3014)

Changsha, Hunan, 410013, China

No email / +86 13319602869

Status: Recruiting

The First Affiliated Hospital of Soochow University ( Site 3040)

Suzhou, Jiangsu, 215006, China

No email / 0512-67972858

Status: Recruiting

The Second Affiliated Hospital of Nanchang University-Oncology Department ( Site 3037)

Nanchang, Jiangxi, 330006, China

No email / 1-888-577-8839

Status: Recruiting

Jilin Province Tumor Hospital ( Site 3018)

Changchun, Jilin, 130000, China

No email / 1-888-577-8839

Status: Recruiting

LinYi Cancer Hospital-Gastrology department ( Site 3024)

Linyi, Shandong, 276000, China

No email / 0539-768371

Status: Recruiting

Fudan University Shanghai Cancer Center-medical oncology ( Site 3009)

Shanghai, Shanghai Municipality, 200032, China

No email / 021-54561523

Status: Recruiting

Renji Hosp,Shanghai Jiao Tong University School of Medicine ( Site 3042)

Shanghai, Shanghai Municipality, 200127, China

No email / 021-68383312

Status: Recruiting

Zhongshan Hospital,Fudan University-Oncology ( Site 3003)

Shanghai, Shanghai Municipality, 200032, China

No email / 021-31151990

Status: Recruiting

Beijing Anzhen Nanchong Hospital of Capital Medical University (Nanchong Central Hospital) ( Site 3029)

Nanchong, Sichuan, 637199, China

No email / +868173460120

Status: Recruiting

Sichuan Cancer hospital. ( Site 3030)

Chengdu, Sichuan, 610213, China

No email / 028-85420501

Status: Recruiting

West China Hospital, Sichuan University ( Site 3035)

Chengdu, Sichuan, 610041, China

No email / (028)85422114

Status: Recruiting

Xinjiang Medical University Cancer Hospital - Urumchi-The No.11 of Surgery building ( Site 3010)

Ürümqi, Xinjiang, 830011, China

No email / 0991-7819430

Status: Recruiting

Yunnan Province Cancer Hospital ( Site 3031)

Kunming, Yunnan, 650107, China

No email / 0871-68178134

Status: Recruiting

Sir Run Run Shaw Hospital of Zhejiang University School of Medicine-Oncology ( Site 3006)

Hangzhou, Zhejiang, 310016, China

No email / 0571886921

Status: Recruiting

Taizhou Hospital of Zhejiang Province ( Site 3020)

Linhai, Zhejiang, 317000, China

No email / 0576-85120120

Status: Recruiting

Yueqing People's Hospital ( Site 3041)

Yueqing, Zhejiang, 325699, China

No email / 057762061260

Status: Recruiting

Zhejiang Cancer Hospital-Oncology ( Site 3021)

Hangzhou, Zhejiang, 310022, China

No email / 1-888-577-8839

Status: Recruiting

Centro Cancerológico del Caribe (CECAC) ( Site 0606)

Barranquilla, Atlántico, 080001, Colombia

No email / 3132121774

Status: Recruiting

Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0603)

Bogotá, Bogota D.C., 111321, Colombia

No email / 576015948660x5715593

Status: Recruiting

FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0602)

Bogotá, Bogota D.C., 110131, Colombia

No email / +576017454421

Status: Recruiting

Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0600)

Valledupar, Cesar Department, 200001, Colombia

No email / +57 315 8505190

Status: Recruiting

Fundación Valle del Lili-Fundacion Valle del Lili ( Site 0607)

Santiago de Cali, Valle del Cauca Department, 760032, Colombia

No email / +576023319090 - 4022

Status: Recruiting

Rigshospitalet ( Site 1102)

Copenhagen, Capital Region, 2100, Denmark

No email / +45 35453545

Status: Recruiting

Aalborg Universitetshospital, Syd-Department of Oncology ( Site 1103)

Aalborg, North Denmark, 9000, Denmark

No email / +45 97660000

Status: Recruiting

Odense Universitetshospital-Department of oncology ( Site 1101)

Odense, Region Syddanmark, 5000, Denmark

No email / +45 24432924

Status: Recruiting

Hôpital Saint-Louis ( Site 1201)

Paris, 75475, France

No email / +33142494041

Status: Recruiting

Institut Bergonié - Centre Régional de Lutte Contre Le Cance-Medical Oncology ( Site 1211)

Bordeaux, Aquitaine, 33076, France

No email / +33 5 56 33 32 78

Status: Recruiting

CENTRE LEON BERARD-Medical oncology ( Site 1208)

Lyon, Auvergne-Rhône-Alpes, 69008, France

No email / 33 4 78 78 59 92

Status: Recruiting

Centre François Baclesse ( Site 1202)

Caen, Calvados, 14076, France

No email / +33 2 31 45 50 50

Status: Recruiting

CHU Rangueil-Digestive oncology department ( Site 1210)

Toulouse, Haute-Garonne, 31059, France

No email / +33561322142

Status: Recruiting

Centre Oscar Lambret ( Site 1206)

Lille, Hauts-de-France, 59020, France

No email / +33 03 20 29 58 30

Status: Recruiting

Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 1203)

Rennes, Ille-et-Vilaine, 35042, France

No email / +33299252976

Status: Recruiting

Centre Hospitalier Universitaire de Poitiers ( Site 1209)

Poitiers, Vienne, 86021, France

No email / +33549444951

Status: Recruiting

Institut Mutualiste Montsouris-Oncology ( Site 1216)

Paris, Île-de-France Region, 75014, France

No email / +33 01 56 61 63 77

Status: Recruiting

Charité Campus Virchow-Klinikum-Klinik Hämatologie Onkologie Tumorimmunologie ( Site 1304)

Berlin, 13353, Germany

No email / +4930450653192

Status: Recruiting

Facharztzentrum Eppendorf-Facharztzentrum Eppendorf ( Site 1300)

Hamburg, 20249, Germany

No email / +4940360352247

Status: Recruiting

NCT-Department of Medical Oncology ( Site 1302)

Heidelberg, Baden-Wurttemberg, 69120, Germany

No email / +496221566857

Status: Recruiting

Universitätsmedizin Göttingen - Georg-August-Universität ( Site 1310)

Göttingen, Lower Saxony, 37075, Germany

No email / +4905513963879

Status: Recruiting

Universitaetsklinikum Carl Gustav Carus Dresden-Medical Dept I - Medical Oncology ( Site 1307)

Dresden, Saxony, 01307, Germany

No email / +49035145818004

Status: Recruiting

Städtisches Krankenhaus Kiel-2. Medizinische Klinik ( Site 1306)

Kiel, Schleswig-Holstein, 24116, Germany

No email / +4943116971272

Status: Recruiting

Prince of Wales Hospital ( Site 3102)

Shatin, Hong Kong

No email / + 852 3505 2211

Status: Recruiting

Queen Elizabeth Hospital ( Site 3101)

Yau Ma Tei, 999077, Hong Kong

No email / +852 3506 8888

Status: Recruiting

Queen Mary Hospital ( Site 3100)

Hong Kong, Hong Kong

No email / +852 2255 3838

Status: Recruiting

Hadassah Medical Center ( Site 1603)

Jerusalem, 9112001, Israel

No email / +972-538220805

Status: Recruiting

Hillel Yaffe Medical Center ( Site 1604)

Hadera, 3810101, Israel

No email / +972-544512396

Status: Recruiting

Rabin Medical Center ( Site 1605)

Petah Tikva, 4941492, Israel

No email / +972-505533121

Status: Recruiting

Rambam Health Care Campus-Oncology Division ( Site 1600)

Haifa, 3109601, Israel

No email / 04-7776234

Status: Recruiting

Sourasky Medical Center ( Site 1602)

Tel Aviv, 64239, Israel

No email / 03-6947832

Status: Recruiting

Ospedale San Raffaele-Oncologia Medica ( Site 1701)

Milan, 20132, Italy

No email / 02 2643 3169

Status: Recruiting

Azienda Ospedaliera Universitaria dell'Università "Luigi Van-UOC Oncoematologia ( Site 1704)

Napoli, Campania, 80131, Italy

No email / 00390815666729

Status: Recruiting

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 1703)

Rome, Lazio, 00168, Italy

No email / 00390630154953

Status: Recruiting

Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1700)

Milan, Lombardy, 20133, Italy

No email / +390223903822

Status: Recruiting

Azienda Ospedaliero Universitaria Pisana ( Site 1702)

Pisa, Tuscany, 56126, Italy

No email / 0039050992455

Status: Recruiting

Pantai Hospital Kuala Lumpur-Cancer Centre ( Site 3408)

Kuala Lumpur, 59100, Malaysia

No email / +60327814519

Status: Recruiting

University Malaya Medical Centre-Clinical Oncology ( Site 3402)

Kuala Lumpur, 50603, Malaysia

No email / +60479492351

Status: Recruiting

Hospital Pulau Pinang ( Site 3403)

George Town, Pulau Pinang, 10450, Malaysia

No email / +6042225767

Status: Recruiting

National Cancer Institute-Radiotherapy and Oncology ( Site 3404)

Putrajaya, Putrajaya, 62250, Malaysia

No email / +60388925418

Status: Recruiting

Sarawak General Hospital-Radiotherapy Unit ( Site 3401)

Kuching, Sarawak, 93586, Malaysia

No email / +6082276820

Status: Recruiting

CANCER TREAMTENT CLINIC AND CLINICAL TRIALS SA DE CV ( Site 0814)

Guadalajara, Jalisco, 44260, Mexico

No email / +523316063096

Status: Recruiting

COI Centro Oncologico Internacional S.A.P.I. de C.V.-Investigation Unit COI ( Site 0802)

Mexico City, Mexico City, 04700, Mexico

No email / +528008773264

Status: Recruiting

Centro de Investigacion Clinica de Oaxaca ( Site 0810)

Oaxaca City, Oaxaca, 68020, Mexico

No email / +529512570569

Status: Recruiting

Centro Potosino de Investigación Médica ( Site 0801)

San Luis Potosí City, San Luis Potosí, 78250, Mexico

No email / +52144444752715

Status: Recruiting

Clínica Internacional - Sede San Borja ( Site 0906)

Lima, 15036, Peru

No email / +5116196161 - 5563

Status: Recruiting

INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-Medical Oncology ( Site 0900)

Lima, 15038, Peru

No email / +51012016500

Status: Recruiting

IPOR Instituto Peruano de Oncología & Radioterapia-Centro de Investigación ( Site 0905)

Lima, 15036, Peru

No email / 1-888-577-8839

Status: Recruiting

Instituto Regional de Enfermedades Neoplasicas del Centro (IREN CENTRO) ( Site 0904)

Concepción, Departamento de Junín, 12125, Peru

No email / +51958864658

Status: Recruiting

Hospital de Alta Complejidad La Libertad-Unidad de Investigación en Oncología ( Site 0902)

Trujillo, La Libertad, 13002, Peru

No email / +5144480860

Status: Recruiting

Clínicas AUNA Sede Chiclayo ( Site 0907)

Chiclayo, Lambayeque, 14001, Peru

No email / 1-888-577-8839

Status: Recruiting

Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1807)

Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland

No email / 52 374 35 89

Status: Recruiting

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Onkologii i Radioterapii ( Site 1800)

Warsaw, Masovian Voivodeship, 02-034, Poland

No email / 22 546 20 00

Status: Recruiting

Bialostockie Centrum Onkologii ( Site 1804)

Bialystok, Podlaskie Voivodeship, 15-027, Poland

No email / 85 66 46 734

Status: Recruiting

Szpitale Pomorskie Sp. z o. o.-Oddział Onkologii Klinicznej " Profil Jednego Dnia " ( Site 1810)

Gdynia, Pomeranian Voivodeship, 81-519, Poland

No email / 58 72 60 964

Status: Recruiting

Szpital Wojewódzki w Koszalinie. ( Site 1801)

Poland, West Pomeranian Voivodeship, 75-581, Poland

No email / +48943488930

Status: Recruiting

Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 1811)

Kielce, Świętokrzyskie Voivodeship, 25-734, Poland

No email / 41 345 56 51

Status: Recruiting

Asan Medical Center-Department of Oncology ( Site 3501)

Seoul, 05505, South Korea

No email / +82-2-3010-5935

Status: Recruiting

Samsung Medical Center-Division of Hematology/Oncology ( Site 3502)

Seoul, 06351, South Korea

No email / +82234101779

Status: Recruiting

Seoul National University Hospital-Oncology ( Site 3503)

Seoul, 03080, South Korea

No email / +82260720795

Status: Recruiting

Severance Hospital, Yonsei University Health System-Medical oncology ( Site 3500)

Seoul, 03722, South Korea

No email / 02-2228-8053

Status: Recruiting

The Catholic Univ. of Korea Seoul St. Mary's Hospital ( Site 3505)

Seoul, 06591, South Korea

No email / 02-2258-6046

Status: Recruiting

Seoul National University Bundang Hospital ( Site 3504)

Seongnam, Kyonggi-do, 13620, South Korea

No email / +82-31-787-7037

Status: Recruiting

Hospital Clinico San Carlos ( Site 1903)

Madrid, 28040, Spain

No email / +34 917044789

Status: Recruiting

Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1900)

Barcelona, 08035, Spain

No email / 34 93 274 60 00

Status: Recruiting

Hospital Universitario Marqués de Valdecilla ( Site 1901)

Santander, Cantabria, 39008, Spain

No email / +34942203424

Status: Recruiting

CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 1905)

A Coruña, La Coruna, 15006, Spain

No email / 34 981178000 x291476

Status: Recruiting

COMPLEJO HOSPITALARIO DE NAVARRA-Medical Oncology ( Site 1904)

Pamplona, Navarre, 31009, Spain

No email / 848422222

Status: Recruiting

Hospital Universitario Central de Asturias-Medical Oncology ( Site 1902)

Oviedo, Principality of Asturias, 33011, Spain

No email / 34 985108000x36582

Status: Recruiting

Chang Gung Medical Foundation-Linkou Branch ( Site 3602)

Taoyuan District, 33305, Taiwan

No email / +88633281200x8825

Status: Recruiting

China Medical University Hospital ( Site 3603)

Taichung, 404332, Taiwan

No email / +886422052121x15057

Status: Recruiting

National Cheng Kung University Hospital-Clinical Trial Center ( Site 3604)

Tainan City, 704, Taiwan

No email / +88662353535x6550

Status: Recruiting

National Taiwan University Hospital ( Site 3600)

Taipei, 10002, Taiwan

No email / +886223123456x67514

Status: Recruiting

Taipei Veterans General Hospital ( Site 3601)

Taipei, 112, Taiwan

No email / +886228712121

Status: Recruiting

Chulalongkorn University ( Site 3702)

Bangkok, Bangkok, 10330, Thailand

No email / 662564533

Status: Recruiting

Faculty of Medicine Siriraj Hospital ( Site 3700)

Bangkok, Bangkok, 10700, Thailand

No email / 6624194488

Status: Recruiting

Songklanagarind hospital ( Site 3701)

Hat Yai, Changwat Songkhla, 90110, Thailand

No email / 66810967363

Status: Recruiting

Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 2101)

Ankara, 06800, Turkey (Türkiye)

No email / 903125526000

Status: Recruiting

Atatürk Üniversitesi-onkoloji ( Site 2111)

Erzurum, 25070, Turkey (Türkiye)

No email / 904423447232

Status: Recruiting

Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 2104)

Adana, 01250, Turkey (Türkiye)

No email / 903223444444

Status: Recruiting

Dicle Üniversitesi-oncology ( Site 2108)

Diyarbakır, 21100, Turkey (Türkiye)

No email / +904122411019 - 5658

Status: Recruiting

Hacettepe Universite Hastaneleri-oncology hospital ( Site 2100)

Ankara, 06230, Turkey (Türkiye)

No email / +903125956000

Status: Recruiting

Samsun Medical Park Hastanesi-medical oncology ( Site 2110)

Samsun, 55200, Turkey (Türkiye)

No email / +90 362 311 40 40

Status: Recruiting

TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2106)

Istanbul, 34722, Turkey (Türkiye)

No email / +90 (216) 606 52 00

Status: Recruiting

Yuzuncu Yil University Dursun Odaba Tp Merkezi-Medical Oncology ( Site 2109)

Van, 65200, Turkey (Türkiye)

No email / +90 432 215 04 70

Status: Recruiting

The Christie NHS Foundation Trust-Medical Oncology ( Site 2201)

Manchester, m20 4bx, United Kingdom

No email / +441614463000

Status: Recruiting

Addenbrooke's Hospital ( Site 2203)

Cambridge, Cambridgeshire, CB2 2QQ, United Kingdom

No email / 1-888-577-8839

Status: Recruiting

Ninewells Hospital and Medical School-Oncology Petty ( Site 2209)

Dundee, Dundee City, DD2 1SG, United Kingdom

No email / 1-888-577-8839

Status: Recruiting

St Bartholomew's Hospital ( Site 2206)

London, London, City of, EC1A 7BE, United Kingdom

No email / 1-888-577-8839

Status: Recruiting

Banner MD Anderson Cancer Center ( Site 0119)

Gilbert, Arizona, 85234, United States

No email / 888-577-8839

Status: Recruiting

UCLA Hematology/Oncology - Santa Monica ( Site 0140)

Los Angeles, California, 90404, United States

No email / 888-577-8839

Status: Recruiting

AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0129)

Orlando, Florida, 32804, United States

No email / 888-577-8839

Status: Recruiting

University of Chicago Medical Center ( Site 0120)

Chicago, Illinois, 60637, United States

No email / 888-577-8839

Status: Recruiting

Norton Audubon Hospital-Norton Cancer Institute - Audubon ( Site 0105)

Louisville, Kentucky, 40217, United States

No email / 888-577-8839

Status: Recruiting

The University of Louisville, James Graham Brown Cancer Center-James Graham Brown Cancer Center ( Site 0113)

Louisville, Kentucky, 40202, United States

No email / 888-577-8839

Status: Recruiting

University of Kentucky Chandler Medical Center-Medical Oncology ( Site 0124)

Lexington, Kentucky, 40536, United States

No email / 859-257-4488

Status: Recruiting

Henry Ford Hospital ( Site 0107)

Detroit, Michigan, 48202, United States

No email / 888-577-8839

Status: Recruiting

Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0138)

Fargo, North Dakota, 58122, United States

No email / 888-577-8839

Status: Recruiting

Oregon Health and Science University ( Site 0104)

Portland, Oregon, 97239, United States

No email / 888-577-8839

Status: Recruiting

UPMC Hillman Cancer Center ( Site 0126)

Pittsburgh, Pennsylvania, 15232, United States

No email / 888-577-8839

Status: Recruiting

MUSC Hollings Cancer Center-Hematology Oncology ( Site 0122)

Charleston, South Carolina, 29425, United States

No email / 888-577-8839

Status: Recruiting

Sanford Cancer Center ( Site 0136)

Sioux Falls, South Dakota, 57104, United States

No email / 888-577-8839

Status: Recruiting

The West Clinic, PLLC dba West Cancer Center ( Site 0110)

Germantown, Tennessee, 38138, United States

No email / 901-683-0055

Status: Recruiting

Inova Schar Cancer ( Site 0106)

Fairfax, Virginia, 22031, United States

No email / 571-472-4724

Status: Recruiting

Fred Hutchinson Cancer Center ( Site 0111)

Seattle, Washington, 98109, United States

No email / 888-577-8839

Status: Recruiting